(TheNewswire)
Calgary, Alberta - TheNewswire- September 14, 2021 - Voyageur Pharmaceuticals Ltd.(TSXV:VM) ( OTC: VYYRF) (the "Company" or"Voyageur") develops, manufactures and will commercializehigh-performance cost effective imaging contrast agents for themedical radiology marketplace. Today the Company announced theformation of its Scientific Advisory Board (SAB) to support thefirm’s research, clinical and product development programs. The SABis to provide our management team, BOD and our imaging consultantsDash International with expert advice and counsel that fulfills ourmission and our vision to provide products that will benefit thehealthcare system worldwide. In addition, the SAB will assist withoutreach to the medical and scientific community, guide and overseeVoyageur’s innovative programs and bring strategic perspectives torapidly emerging science and technology trends impactingVoyageur.
The SAB comes together with the following leadingimaging physicians and researchers:
Alec J. Megibow, MD
-
- Professor, Department of Radiology, NYU GrossmanSchool of Medicine
- Professor, Department of Surgery, NYU Grossman Schoolof Medicine
- Director, FPO Outpatient Imaging Services, NYULangone Health
- Interests: CT and MRI, liver, pancreas, andalimentary tract
C. Daniel Johnson, MD
-
- Professor of Radiology, Mayo College of Medicine andScience
- Consultant, Department of Radiology, Mayo Clinic,Scottsdale AZ.
- Consultant, Department of Radiology, Mayo Clinic,Rochester, MN
- Adjunct Faculty, College of Health Solutions, ArizonaState University.
- Interests: Full structural colorectal screeningexamination using CT Colonography. Includes exam performance, patientacceptance, cost effectiveness, image display technology, software andCT technology.
Thomas Lauenstein, MD
-
- Medical Director, Evangelical Hospital, Düsseldorf,Germany
- Interventional Radiology for oncology (SIRT/TACE)
- Interests: Abdominal imaging with a focus on liver,pancreas and bowel. Hybrid imaging (PET/CT) and (PET/MRI)
“We are excited to have such preeminent leaders intheir fields joining our SAB” said Brent Willis, CEO of VoyageurPharmaceuticals Ltd. ”We believe their participation reflects theseriousness of our mission, our strategy and the disruptive promise ofour imaging contrast agents. We will benefit from their years ofexperience and deep expertise as we continue to advance our portfolioof programs and products”.
About Voyageur
Voyageur is a Canadian public company listed on theTSXV under the trading symbol VM. Voyageur is focused on thedevelopment of barite and iodine Active Pharmaceutical Ingredients(API) and high-performance cost-effective imaging contrast agents forthe medical radiology marketplace. Voyageur’s goal is to initiallygenerate positive cash flow from operations using third party GMPpharmaceutical manufacturers in Canada and internationally.Ultimately, Voyageur has plans to build all the requiredinfrastructure to become 100% self-sufficient with all manufacturing.Voyageur owns a 100% interest in three barium sulfate (barite)projects including the Frances Creek property, suitable in grade forthe pharmaceutical barite marketplace, with interests in a high-gradeiodine, lithium & bromine brine project located in Utah,USA.
Voyageur is moving forward with its business plan ofbecoming the only fully integrated company in the radiology medicalfield, by controlling all primary input costs under the motto of:"From the Earth to the Bottle".
For Further Media Information or to set up aninterview, please contact:
Brent Willis
President & CEO
Ron Love
CFO
T 403.818.6086
Forward Looking Information
This news release may contain certain forward-lookinginformation and statements, including without limitation, statementspertaining to the preparation and timing of the PEA for Francis Creek,the ability of the upgrading system to process large volumes ofbarium, the market for the Company's products, the plant design andcosts and the costs for Voyageur to produce natural barium sulfate,the costs to produce man-made barium sulfate, and statements relatingto the Company's long term plans, including with respect to becoming100% self-sufficient with all manufacturing. All statements includedherein, other than statements of historical fact, are forward-lookinginformation and such information involves various risks anduncertainties. There can be no assurance that such information willprove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR website atwww.sedar.com. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.
Reader Advisory
Neither the TSXV nor its Regulation Services Provider(as that term is defined in the policies of the TSXV) acceptsresponsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2021 TheNewswire - All rights reserved.